Get access

ORIGINAL RESEARCH—ENDOCRINOLOGY: Long-Acting Intramuscular Testosterone Undecanoate for Treatment of Female-to-Male Transgender Individuals

Authors

  • Jens W. Jacobeit MD,

    Corresponding author
    1. ENDOKRINOLOGIKUM Hamburg, Center for Hormonal and Metabolic Diseases, Reproductive Endocrinology, Hamburg, Germany;
      Jens W. Jacobeit, MD, ENDOKRINOLOGIKUM Hamburg, Zentrum für Hormon- und Stoffwechselerkrankungen, Reproduktionsmedizin und Gynäkologische Endokrinologie, Lornsenstraße 4–6, 22767 Hamburg, Germany. Tel: +49 40 30628 200; Fax: +49 40 30628 239; E-mail: jens.jacobeit@endokrinologikum.com
    Search for more papers by this author
  • Louis J. Gooren MD,

    1. Department of Endocrinology, Andrology Section, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Search for more papers by this author
  • Heinrich M. Schulte MD

    1. ENDOKRINOLOGIKUM Hamburg, Center for Hormonal and Metabolic Diseases, Reproductive Endocrinology, Hamburg, Germany;
    Search for more papers by this author

Jens W. Jacobeit, MD, ENDOKRINOLOGIKUM Hamburg, Zentrum für Hormon- und Stoffwechselerkrankungen, Reproduktionsmedizin und Gynäkologische Endokrinologie, Lornsenstraße 4–6, 22767 Hamburg, Germany. Tel: +49 40 30628 200; Fax: +49 40 30628 239; E-mail: jens.jacobeit@endokrinologikum.com

ABSTRACT

Aim.  Testosterone treatment is essential for the induction and maintenance of virilization of female-to-male transsexuals. This study tested the suitability of a novel testosterone preparation for this purpose.

Methods.  Parenteral long-acting testosterone undecanoate (TU) was administered to 12 female-to-male transsexuals. Observations were made while subjects received treatment.

Main Outcome Measures.  Virilization of female-to-male transsexuals and side effects of testosterone administration.

Results.  The testosterone levels were largely identical to those in hypogonadal men receiving testosterone treatment with TU. There were no side effects. There was a small but significant decrease in plasma cholesterol and low-density lipoprotein, but plasma high-density lipoprotein did not change significantly. Both levels of hemoglobin and hematocrit rose upon administration but remained within the physiological range.

Conclusions.  TU is suited for induction of virilization in female-to-male transsexuals without significant side effects. Jacobeit JW, Gooren LJ, and Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med 2007;4:1479–1484.

Get access to the full text of this article

Ancillary